Confronto
Leuprorelin vs. Bremelanotide
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
53714-56-0
189691-06-3
Peso molecolare
1209.4 g/mol
1025.18 g/mol
Emivita
3 h
2.7 h
Sequenza
Pyr-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEtAc-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OHMeccanismo d'azione
Leuprorelin
Leuprorelin is a GnRH-receptor agonist. After binding to pituitary GnRH receptors, it first causes a transient surge in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release — the so-called flare. With continuous, non-pulsatile exposure the receptors are downregulated and desensitized, suppressing gonadotropin secretion and consequently lowering sex steroids (testosterone or estradiol) to low levels. This mechanism underlies the literature-described use in hormone-dependent conditions.
Bremelanotide
Bremelanotide is a cyclic peptide that binds non-selectively to melanocortin receptors (MC1R through MC5R) — with highest affinity at MC4R in the central nervous system. The precise role of MC4R activation in sexual behaviour is not fully understood; animal data show effects on hypothalamic circuits. Peripheral effects (blood pressure, hyperpigmentation) are attributed to MC1R/MC2R.
Base di evidenze
Evidenza più alta
RCT sull'uomo
RCT sull'uomo
Studi
4
5
di cui sull'uomo
4
5
Effetti registrati
4
3
Contraddizioni aperte
1
1
Eventi avversi documentati
3
2
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Leuprorelin and Bremelanotide?
- Leuprorelin is classified as "Ricerca (altro)", while Bremelanotide is classified as "Ricerca (altro)". Leuprorelin: Leuprorelin (also leuprolide) is a synthetic nonapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH). It is an approved prescription medicine in several jurisdictions, including for advanced prostate cancer, endometriosis, uterine fibroids and central precocious puberty. This page neutrally summarizes the evidence base and legal status and is not a usage or dosing recommendation. Bremelanotide: Synthetic cyclic heptapeptide acting as a non-selective melanocortin-receptor agonist. FDA-approved in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in pre-menopausal women. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Leuprorelin or Bremelanotide?
- The highest available evidence level is "RCT sull'uomo" for Leuprorelin and "RCT sull'uomo" for Bremelanotide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Leuprorelin and Bremelanotide in Germany and the United States?
- Germania: Leuprorelin — Su prescrizione, Bremelanotide — Non approvato. Stati Uniti: Leuprorelin — Su prescrizione, Bremelanotide — Su prescrizione. These are factual summaries with source and review date on the individual pages.